EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MATTERHORN—the new perioperative standard for resectable gastric and gastroesophageal junction cancer

Florian Huemer, Lukas Weiss

memo - Magazine of European Medical Oncology · 2026-05 · 19 (2) · 75-79

DOI: 10.1007/s12254-026-01106-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift memo - Magazine of European Medical Oncology, online erschienen am 20.03.2026. Verfasst von Florian Huemer und 1 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paracelsus Medical University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Positive results of the FLOT4-AIO trial in 2019 have established perioperative chemotherapy with FLOT (5-fluorouracil [5-FU], oxaliplatin, and docetaxel) as the standard approach for resectable adenocarcinoma of the stomach and gastroesophageal junction. Despite the improvement of clinical outcome when compared to the former anthracycline-based triplet chemotherapy, more than half of patients experience disease relapse and/or death with perioperative FLOT during follow-up. While the phase 3 KEYNOTE-585 trial—investigating the addition of pembrolizumab to the chemotherapy backbone cisplatin +5-FU/capecitabine—was a negative trial, the phase 3 MATTERHORN trial demonstrated superiority of FLOT combined with durvalumab (D-FLOT) compared to FLOT alone in terms of improved event-free survival (EFS) and overall survival (OS) and established D‑FLOT as the new standard of care for all-comers. Preliminary results of the ongoing DANTE phase 3 trial corroborate higher pathological complete remission (pCR) rates by combining perioperative FLOT + immune checkpoint blockade; however, EFS and OS results are pending. In light of the encouraging pCR rates achieved by the addition of pembrolizumab and trastuzumab to FLOT in HER2+ disease in the single-arm PHERFLOT phase 2 trial, the use of additional trastuzumab in this subgroup warrants further investigation.

Förderung

  • Paracelsus Medical University

Zitieren

APA

Huemer, F., & Weiss, L. (2026). MATTERHORN—the new perioperative standard for resectable gastric and gastroesophageal junction cancer. memo - Magazine of European Medical Oncology, 19(2), 75-79. https://doi.org/10.1007/s12254-026-01106-2

Vancouver

Huemer F, Weiss L. MATTERHORN—the new perioperative standard for resectable gastric and gastroesophageal junction cancer. memo - Magazine of European Medical Oncology. 2026;19(2):75-79. doi:10.1007/s12254-026-01106-2

BibTeX
@article{Huemer2026,
  author = {Huemer, Florian and Weiss, Lukas},
  title = {MATTERHORN—the new perioperative standard for resectable gastric and gastroesophageal junction cancer},
  journal = {memo - Magazine of European Medical Oncology},
  year = {2026},
  volume = {19},
  number = {2},
  pages = {75--79},
  doi = {10.1007/s12254-026-01106-2}
}
Kostenlos starten →